Eyal Baror will speak in this conference - Wednesday, May 31 10:40 - Treatments for Alzheimer's and Cognitive Disorders
Globally, the population continues to age and the number of dementia patients keeps expanding. Ongoing efforts to develop disease modifying therapies have been plagued with failures. What new avenues are being pursued to address the growing global need? Will novel diagnostics allow us to initiate treatments earlier? What non-pharmacological options are in development?
Panelists: Casey Lynch, CEO, Cortexyme
Mark Gurney, CEO, Tetra Discovery Partners
Eyal Baror, CEO and President, Neuronix
Now in its 12th year, the Neurotech Investing and
Partnering Conference is the premier partnering and investing conference for the neurotechnology industry, spanning pharmaceuticals, medical devices, software and diagnostics for thebrain and nervous system.
Organized by the Neurotechnology Industry Organization and Cambridge Innovation Institute, the 12th annual conference will be held on Wednesday and Thursday, May 31-June 1, 2017 at The Park Central San Francisco Hotel, San Francisco, CA.
The Neurotech Investing and Partnering Conference is a global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry.
This market-defining conference features keynotes on the state of the neurotech industry, cutting edge company presentations, leading translational research projects and panel discussions on a comprehensive selection of neurotech topics.